In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting ...

Metastatic castration-resistant prostate cancer is an advanced stage of prostate cancer that progresses despite hormone ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The ...

Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.

Since the introduction of 68-Ga-Prostate-specific-membran-Antigen-positron- Computertomography (PSMA-PET) it is possible to identify prostate cancer patients in an early oligometastatic state of their ...

This nationwide register-based cohort study examined the association between castration status and postoperative survival in men who had undergone surgery for spinal metastases from prostate cancer.

Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat ...

OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response. This is an ASCO Meeting ...

Implementing comprehensive population-wide genomic testing in metastatic prostate cancer (mPCa): A real-world Canadian cohort study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.